Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Merck
Johnson and Johnson
McKesson
AstraZeneca
Mallinckrodt
Boehringer Ingelheim

Last Updated: December 9, 2019

DrugPatentWatch Database Preview

Salmeterol xinafoate - Generic Drug Details

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What are the generic drug sources for salmeterol xinafoate and what is the scope of freedom to operate?

Salmeterol xinafoate is the generic ingredient in one branded drug marketed by Glaxosmithkline and is included in two NDAs. Additional information is available in the individual branded drug profile pages.

There are nineteen drug master file entries for salmeterol xinafoate. One supplier is listed for this compound.

Recent Clinical Trials for salmeterol xinafoate

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Respirent Pharmaceuticals Co Ltd.Phase 1
BECRO Ltd.Phase 1
Shanghai Biomabs Pharmaceutical Co., Ltd.Phase 3

See all salmeterol xinafoate clinical trials

Recent Litigation for salmeterol xinafoate

Identify potential future generic entrants

District Court Litigation
Case NameDate
Meda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc.2015-09-08
Ted Miller Dairy LLC2010-02-17

See all salmeterol xinafoate litigation

Pharmacology for salmeterol xinafoate
Medical Subject Heading (MeSH) Categories for salmeterol xinafoate
Synonyms for salmeterol xinafoate
( inverted exclamation markA) 4-Hydroxy-a1-[[[6-(4-phenylbutoxy)hexyl]amino]m-ethyl]-1,3-benzenedimethanol xinafoate
(+-)-4-Hydroxy-alpha(sup 1)-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-m-xylene-alpha,alpha'-diol 1-hydroxy-2-naphthoate (salt)
(+/-) 4-Hydroxy-a1-[[[6-(4-phenylbutoxy)hexyl]amino]m-ethyl]-1,3-benzenedimethanol xinafoate
1,3-Benzenedimethanol, 4-hydroxy-alpha(sup 1)-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-, (+-)-, 1-hydroxy-2-naphthalenecarboxylate (salt)
2-(Hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]phenol 1-hydroxy-2-naphthoate
2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]phenol; 1-hydroxynaphthalene-2-carboxylic acid
2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]phenol;1-hydroxynaphthalene-2-carboxylic acid
4-(1-Hydroxy-2-((6-(4-phenylbutoxy)hexyl)amino)ethyl)-2-(hydroxymethyl)phenol 1-hydroxy-2-naphthoate
4-(1-hydroxy-2-(6-(4-phenylbutoxy)hexylamino)ethyl)-2-(hydroxymethyl)phenol 1-hydroxy-2-naphthoate
4-[1-Hydroxy-2-[[6-(4-phenylbutoxy)hexyl]amino]ethyl]-2-(hydroxymethyl)phenol 1-Hydroxy-2-naphthoate
4-Hydroxy-?1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-1,3-benzenedimethanol 1-hydroxy-2-naphthalenecarboxylic acid salt
4-Hydroxy-|A1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-1,3-benzenedimethanol 1-Hydroxy-2-naphthalenecarboxylic Acid
4-Hydroxy-alpha-({[6-(4-phenylbutoxy)hexyl]amino}methyl)-1,3-benzenedimethanol xinafoate
4CA-1124
89365-50-4 (Parent)
94749-08-3
AB0020656
AC1L1LPS
AKOS016004957
AN-8181
ANW-61823
Arial
Asmerole
BC208521
BCP04778
BCP0726000003
Beglan
Betamican
C25H37NO4.C11H8O3
C36H45NO7
CAS-94749-08-3
CHEBI:9012
CHEMBL1082607
CS-1527
CTK8B9015
D00687
Dilamax
DSSTox_CID_25798
DSSTox_GSID_45798
DSSTox_RID_81137
DTXSID1045798
EU-0101100
FT-0642283
GR 33343 G
GR 33343G
GR 33343X xinafoate
GR 3343G
GR-33343 G
GR-33343-G
gr-33343g
HMS2232I16
HMS3263K22
HY-17453
Inaspir
KB-280789
KS-1140
LP01100
LS-94516
MFCD00897708
MLS001332577
MLS001332578
MolPort-003-850-218
NCGC00015938-05
NCGC00094372-01
NCGC00094372-02
NCGC00094372-03
NCGC00094372-04
NCGC00261785-01
Q-201697
s4296
Salmetedur
Salmeterol (xinafoate)
Salmeterol 1-hydroxy-2-naphthoate
Salmeterol Hydroxynaphthoate
Salmeterol xinafoate (JAN/USAN)
Salmeterol xinafoate [USAN:USP]
Salmeterol xinafoate [USAN]
Salmeterol xinafoate for system suitability, European Pharmacopoeia (EP) Reference Standard
Salmeterol xinafoate, >=98% (HPLC), solid
Salmeterol xinafoate, European Pharmacopoeia (EP) Reference Standard
Salmeterol Xinafoate, Pharmaceutical Secondary Standards; Certified Reference Material
Salmeterol xinafoate, United States Pharmacopeia (USP) Reference Standard
Salmeterol xinafonate
salmeterol, 1-hydroxy-2-naphthoate
SCHEMBL18070
Serevent diskus
Serevent Inhaler and Disks
Siduomi
SMR000875207
SN 408
SR-01000597359
SR-01000597359-1
ST24031610
TC-150568
Tox21_111270
Tox21_111270_1
Tox21_501100
Ultrabeta
V1621
W-5199

US Patents and Regulatory Information for salmeterol xinafoate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline SEREVENT salmeterol xinafoate POWDER;INHALATION 020692-001 Sep 19, 1997 RX Yes Yes   Start Trial   Start Trial   Start Trial
Glaxosmithkline SEREVENT salmeterol xinafoate AEROSOL, METERED;INHALATION 020236-001 Feb 4, 1994 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for salmeterol xinafoate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline SEREVENT salmeterol xinafoate POWDER;INHALATION 020692-001 Sep 19, 1997   Start Trial   Start Trial
Glaxosmithkline SEREVENT salmeterol xinafoate POWDER;INHALATION 020692-001 Sep 19, 1997   Start Trial   Start Trial
Glaxosmithkline SEREVENT salmeterol xinafoate POWDER;INHALATION 020692-001 Sep 19, 1997   Start Trial   Start Trial
Glaxosmithkline SEREVENT salmeterol xinafoate POWDER;INHALATION 020692-001 Sep 19, 1997   Start Trial   Start Trial
Glaxosmithkline SEREVENT salmeterol xinafoate POWDER;INHALATION 020692-001 Sep 19, 1997   Start Trial   Start Trial
Glaxosmithkline SEREVENT salmeterol xinafoate AEROSOL, METERED;INHALATION 020236-001 Feb 4, 1994   Start Trial   Start Trial
Glaxosmithkline SEREVENT salmeterol xinafoate POWDER;INHALATION 020692-001 Sep 19, 1997   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Medtronic
Express Scripts
Boehringer Ingelheim
Mallinckrodt
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.